Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].

STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market. OssDsign launched OssDsign Catalyst in the U.S. in August 2021. Since then, the company has undergone a strategic shift to become a pure-play orthobiologics company and has shown high double-digit growt ...